

**MERCK RESEARCH LABORATORIES**  
Division of Merck & Co., Inc.  
West Point, Pennsylvania 19486

Date: 31-DEC-2008

Re: 0683 Blinded Therapy

Dear Doctor:

This letter is to provide follow-up information on an adverse experience concerning 0683 Blinded Therapy which has been reported to you previously.

U.S. Food and Drug Regulations require sponsors of clinical studies conducted under an IND to notify the FDA of any serious and unexpected adverse experiences occurring in a clinical study filed under that IND when either the investigator or the sponsor believes that there is a reasonable possibility that the experience may have been drug related or if the drug relationship is unknown. The sponsor is also required to inform all investigators working with the particular drug under the IND.

In compliance with these requirements, the enclosed report has been submitted to the FDA and, because you are an investigator in a clinical study under this IND, a copy is enclosed for your information.

Please append this report to the Confidential Investigator's Brochure for the appropriate investigational product or to the Product Circular for the appropriate marketed product and retain in your files.

Please submit a copy of this report promptly (within less than 30 days of receipt) to your Institutional Review Board(s) even though the report may not involve a patient in your study.

This report does not necessarily reflect a conclusion by Merck or the FDA that the drug caused or contributed to the adverse experience. If you have any questions about this report, please contact the Merck monitor for your study.

Enclosure(s): WAES # 0709USA02327, GENSTUDY # 056-0019 AN # 61503

# Merck Human Health Division

For use by user-facilities,  
distributors and manufacturers for  
MANDATORY reporting

Merck Facsimile of FDA Form 3500A  
Approved by FDA (10/21/1993)

## MedWatch

The FDA Medical Products Reporting Program

Page 1

Mfr report #	WAES 0709USA02327
UF/Dist report #	
	FDA Use Onl

A. Patient information			
1. Patient identifier Confidential  AN 61503  in confidence	2. Age at time of event: or 65 years  Date of Birth: 03/17/1942	3. Sex <input type="checkbox"/> Female <input checked="" type="checkbox"/> Male	4. Weight  187 lbs

B. Adverse event or product problem	
1. <input checked="" type="checkbox"/> Adverse event and / or	<input type="checkbox"/> Product problem (e.g., defects/malfunctions)
2. Outcomes attributed to adverse event (check all that apply)	
<input type="checkbox"/> Death (mm/dd/yyyy)	<input type="checkbox"/> Disability or Permanent Damage
<input type="checkbox"/> Life-threatening	<input type="checkbox"/> Congenital Anomaly/Birth Defect
<input checked="" type="checkbox"/> Hospitalization-initial or prolonged	<input type="checkbox"/> Other Serious(Important Medical Events)
<input type="checkbox"/> Required intervention to Prevent Permanent Impairment/Damage (Devices)	

3. Date of event (mm/dd/yyyy)	09/11/2007	4. Date of this report (mm/dd/yyyy)	12/31/2008
5. Describe event or problem			
This is in follow-up to report(s) previously submitted on 9/24/2007; 10/19/2007; 10/29/2007; 10/31/2007; 11/16/2007; 11/20/2007; 1/25/2008; 2/29/2008; 8/20/2008; 9/4/2008; 9/17/2008; 9/22/2008; 9/26/2008; 10/29/2008; 11/14/2008			

A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Initial and follow-up information has been received from an investigator concerning a 65 year old white male with alcohol use, anxiety, deafness, cough, cramps calf, fatigue, gout, heartburn, haemoptysis, insomnia, left and right eye cataract, myalgia, rash, taste changed, umbilical hernia, pain and a history of cerebral commotion, a thoracic CT scan, an abdominal CT scan, a cerebral CT scan, a bronchial biopsy and bronchoscopy who on 31-AUG-2007 was allocated/randomized to a study, title

(Continued on Additional Page)

6. Relevant tests/laboratory data, including dates	Refer to Additional Page
--	--------------------------

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)	MEDICAL HISTORY: Commotio cerebri; Computerised tomogram thorax; Computerised tomogram abdomen; Brain computerised tomography; Bronchoscopy; Biopsy bronchus CONCURRENT CONDITIONS: Alcohol use; Anxiety; Cough; Cramps calf; Fatigue; Pain; Umbilical hernia; Rash; Deafness; Taste changed; Myalgia; Gout;
--	---

(Continued on Additional Page)

C. Suspect medication(s)	
1. Name (Give labeled strength & mfr/labeler)	
# 1	CAP 0683-blinded therapy Unk
# 2	
(Continued on Additional Page)	

2. Dose, frequency & route used	3. Therapy dates (if unknown, give duration) from/to (or best estimate)
# 1 Unk/Unk/PO	# 1 08/31/2007 - 09/13/2007
# 2	# 2

4. Diagnosis for use (indication)	5. Event abated after use stopped or dose reduced.
# 1 Non-small cell lung cancer	yes no N/A unk
# 2	# 1 <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>
	# 2 <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

6. Lot #	7. Exp. Date	8. Event reappeared after reintroduction.
# 1	# 1	yes no N/A unk
# 2	# 2	# 1 <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>
		# 2 <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

9. NDC # or Unique ID	10. Concomitant medical products and therapy dates (excluded treatment of event)
Unknown	PANTOLOC 08/31/2007-12/17/2007 codeine 08/31/2007-12/17/2007
(Continued on Additional Page)	

G. All manufacturers	
1. Contact office - name/address	2. Phone Number
Merck Human Health Division Merck & Co., Inc. P.O. Box 4 West Point, Pa. 19486-0004 Attn: World Wide Product Safety	(215) 652-8071
3. Report source. (check all that apply)	
<input checked="" type="checkbox"/> foreign	
<input checked="" type="checkbox"/> study	
<input type="checkbox"/> literature	
<input type="checkbox"/> consumer	
<input checked="" type="checkbox"/> health professional	
<input type="checkbox"/> user facility	
<input type="checkbox"/> company representative	
<input type="checkbox"/> distributor	
<input type="checkbox"/> other :	

4. Date received by manufacturer (mm/dd/yyyy)	12/23/2008	5. (A)NDA #	
		IND #	58915
6. If IND, protocol #	0560019	STN #	
		PMA/510(k) #	
7. Type of report		Combination Product	<input type="checkbox"/> Yes
<input type="checkbox"/> 5-day	<input type="checkbox"/> 30-day	Pre-1938	<input type="checkbox"/> Yes
<input type="checkbox"/> 7-day	<input type="checkbox"/> Periodic	OTC product	<input type="checkbox"/> Yes
<input type="checkbox"/> 10-day	<input type="checkbox"/> Initial		
<input checked="" type="checkbox"/> 15-day	<input checked="" type="checkbox"/> Follow-up# 15	9. Mfr. report number	WAES 0709USA02327

8. Adverse event term(s)	FEBRILE NEUTROPENIA; FEBRILE NEUTROPENIA; FEBRILE NEUTROPENIA; PNEUMONIA
--------------------------	--

E. Initial reporter	
1. Name, address & phone #	

2. Health professional?	3. Occupation	4. Initial reporter also sent report to FDA.
<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO		<input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> unk

FDA

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

**B. Adverse event or product problem****5. Describe event or problem**

as stated above.

On 31-AUG-2007, the patient was placed on blinded study therapy of either vorinostat 400 mg capsule, 400 mg daily or placebo administered on day(s) -4 through 10 of cycle 1 (cycle equivalent to 25 days) (or days 1 through 14 for each subsequent cycle) for treatment of non-small cell lung cancer (initial diagnosis 06-JUN-2007; current staging 21-AUG-2007: T2/N2/M1/IV).

Concomitant study therapy included paclitaxel, 200 mg/m<sup>2</sup> (388 mg) and carboplatin AUC equivalent to 6 (685 mg) administered intravenous (IV) on day 1 of each treatment cycle). Other concomitant therapy included dolasetron, dexamethasone (manufacturer unknown) famotidine (manufacturer unknown) and diphenhydramine hydrochloride, ibuprofen, indomethacin (manufacturer unknown), codeine and pantoprazole sodium (PANTOLOC).

On 11-SEP-2007, (cycle 1, day 10) the patient was presented to an emergency room with a fever of 38.2C, asthenia, diarrhea, hyponatremia, and myalgia. The patient was diagnosed with febrile neutropenia (grade 3) and was hospitalized. The following lab values were noted: absolute neutrophil count (ANC)  $0.02 \times 10^9/L$ ; platelet count 12,000. Eastern Cooperative Oncology Group (ECOG) rating was equivalent to 3. On 12-SEP-2007 hemoculture was positive. The patient was placed on IV antibiotics cefepime (MAXEPIME) (12-SEP-2007 to 16-SEP-2007), IV, 2 gm, three times a day for febrile neutropenia, filgrastim (NEUPOGEN) (12-SEP-2007 to 14-SEP-2007) for febrile neutropenia, SC die, and received 5 units of platelets for thrombocytopenia. Blinded study therapy was interrupted (last dose administered on 13-SEP-2007). The patient was evaluated by a microbiologist. On 13-SEP-2007, a blood culture was positive for Escherichia coli (E. coli) and the patient's phosphate level was noted to be low (0.37 mmol/L) and was treated with potassium bicarbonate (+) sodium bicarbonate (+) sodium phosphate, monobasic (PHOSPHATE SANDOZ). Subsequently, the patient was treated with metronidazole (FLAGYL) (13-SEP-2007 to 16-SEP-2007) for febrile neutropenia; E. coli bacteremia. On 14-SEP-2007, the patient's potassium level was 3.0 mmol/L (non-serious) and was treated with phosphate potassium. On 16-SEP-2007, IV antibiotics were discontinued. On 17-SEP-2007, the following lab values were noted: ANC  $4.15 \times 10^9/L$ ; platelet count 123,000, and the patient was considered recovered from febrile neutropenia (grade 3). On 18-SEP-2007, the patient was discharged with the discharge diagnosis of E. coli septicemia secondary to febrile neutropenia. On 27-SEP-2007 the patient will be evaluated for Cycle 2 in the outpatient clinic. On 28-SEP-2007, the patient was placed on cycle 2 study therapy. Blinded study therapy was reduced to 200mg daily or placebo. On 05-OCT-2007, the patient's neutrophil count was noted to be 0.58. On 05-OCT-2007 the patient developed neutropenia (grade 3) (non-serious). On 07-OCT-2007 (cycle 2, day 9), at 11:06, the patient presented to an emergency room with fever (38.7 degrees celcius), confusion, dysphagia, sore throat and chills. The patient's absolute neutrophil count was noted to be  $0.11 \times 10^9/L$  and the patient was hospitalized for febrile neutropenia (grade 4). Chest X-ray revealed no particularity and urinalysis lab was normal. Hemoculture test done on 07-OCT-2007 was negative. Blinded study therapy was interrupted. The patient was treated with cefepime (MAXEPIME) (07-OCT-2007 to 10-OCT-2007) 2 gm, IV every 8 hours and filgrastim (NEUPOGEN) (07-OCT-2007 to 09-OCT-2007) for febrile neutropenia. The patient's ANC was 5.08 on 10-OCT-2007. The patient recovered on 11-OCT-2007 and was discharged. The patient's discharge diagnosis was febrile neutropenia. Cycle 3 of blinded study therapy day 1 was initiated on 18-OCT-2007. On 19-OCT-2007 the patient was treated with filgrastim (NEUPOGEN) (19-OCT-2007 to 25-OCT-2007) for neutropenia. On 25-OCT-2007 (Cycle 3, Day 7), the patient presented to the emergency room due to fever (39.1 C), cough, dyspnea and asthenia. Control labs were performed and the patient had an ANC of  $1.39 \times 10^9/L$ . The patient had a respiration rate of 28 per minute and a saturation of 91% on 100%. At the auscultation, the patient had some rale. The patient was hospitalized for febrile neutropenia (grade 2) and pneumonia (grade 3). On 25-OCT-2007, the patient completed cycle 3 study therapy and received IV antibiotics cefepime (MAXEPIME) (25-OCT-2007 to 30-OCT-2007) 2000 mg TID for febrile neutropenia and on 26-OCT-2007 filgrastim (NEUPOGEN) injection "escalate" at 400 mg subcutaneously for febrile neutropenia. The patient was also treated with albuterol sulfate (VENTOLIN) and ipratropium bromide (ATROVENT). Chest x-ray was performed on 26-OCT-2007, the result was pneumonia, no pleural effusion. On 29-OCT-2007, the patient received a blood transfusion for anemia (NSAE). On 31-OCT-2007, the patient was discharged with an ANC of  $4.56 \times 10^9/L$ , no fever, dyspnea or asthenia. On 31-OCT-2007, the patient recovered from febrile neutropenia (grade 2) and pneumonia (grade 3) with sequelae. The patient's discharge diagnoses were pulmonary superinfection, febrile neutropenia and pneumonia. The patient will be evaluated for Cycle 4 on 08-NOV-2007 in an outpatient clinic.

Physical exam on 08-NOV-2007 showed lungs to be clear auscultation. The patient was seen by a physician on 08-NOV-2007 and decided to discontinue patient from study. At the time of the report the patient had not recovered from neutropenia (grade 3) (non-serious).

Other treatment medications administered for non-serious adverse events (NSAE) during the study were: sodium chloride (12-SEP-2007) for hyponatremia; sodium chloride (NaCl 0.9%) (+) potassium chloride (13-SEP-2007 to 15-SEP-2007, 15-SEP-2007 to 18-SEP-2007) for hyponatremia and hypokalemia; potassium bicarbonate (+) sodium phosphate, monobasic (PHOSPHATE-NOVARTIS) (13-SEP-2007 and continuing) for hyponatremia; potassium (14-SEP-2007 and continuing) tablet and potassium phosphate (14-SEP-2007 to 15-SEP-2007) for hypokalemia; vitamin B1 (12-SEP-2007, 13-SEP-2007 to 17-DEC-2007)

and folic acid (12-SEP-2007 to 17-DEC-2007) for use of alcohol; oxazepam (SERAX) (15-SEP-2007) for insomnia; diphenhydramine hydrochloride (BENEDRYL) (15-SEP-2007) for rash. acetaminophen (TYLENOL) (12-SEP-2007 to 30-OCT-2007) for fever; magnesium sulfate (12-SEP-2007) for prophylaxis; aluminum hydroxide (+) diphenhydramine hydrocortisone (+) diphenhydramine (+) nystatin (+) water (MAGIC MOUTHWASH) (12-SEP-2007 to 12-OCT-2007) for prevention of mucositis; benzydamine hydrochloride (TANTUM) (07-OCT-2007 to 10-OCT-2007) for mucositis; gabapentin (NEURONTIN) (12-SEP-2007 to 13-SEP-2007, 14-SEP-2007 and continuing) for myalgia; aluminum hydroxide (+) magnesium hydroxide (MAALOX) (27-OCT-2007) and famotidine IV (07-OCT-2007 to 10-OCT-2007) for heartburn; codeine elixir (14-SEP-2007 to 18-SEP-2007), codeine phosphate (27-OCT-2007 to 30-OCT-2007), STAFEX (27-OCT-2007 to 30-OCT-2007) and morphine syrup (07-OCT-2007 to 10-OCT-2007) for cough; acetaminophen (+) oxycodone hydrochloride (PERCOCET) for thoracic pain (26-OCT-2007); sodium chloride (NACL 0.9%) (07-OCT-2007 to 10-OCT-2007, 26-OCT-2007 to 30-OCT-2007) for hydration; oxygen inhalant (25-OCT-2007 to 26-OCT-2007) and salbutamol (26-OCT-2007 and continuing) for dyspnea; zopiclone for insomnia (28-SEP-2007 to 29-OCT-2007); docusate (27-OCT-2007 to 28-OCT-2007) for prophylaxis use for constipation; enoxaparin sodium (LOVENOX) (27-OCT-2007 to 30-OCT-2007) injection for prophylactic use for phlebitis; ipratropium bromide (ATROVENT) (27-OCT-2007 and continuing); sennosides (27-OCT-2007 to 28-OCT-2007) for prophylactic use for constipation; magnesium hydroxide (28-OCT-2007 to 30-OCT-2007) for prophylaxis use for hypomagnesemia; dolasetron mesylate, famotidine and diphenhydramine (18-OCT-2007) prior to paclitaxel and dexamethasone (17-OCT-2007 to 19-OCT-2007) prior and post paclitaxel.

The reporting investigator felt that febrile neutropenia (1st 2nd and 3rd occurrences) was related to blinded study therapy, carboplatin and paclitaxel and pneumonia (grade 3) was not related to blinded study therapy.

Additional information is not expected.

#### 6. Relevant tests/laboratory data, including dates

##### DIAGNOSTIC TEST

<u>Tests</u>	<u>Date</u>	<u>Value</u>	<u>Unit</u>	<u>Normal Range</u>
blood transfusion	10/29/2007			

##### LABORATORY RESULTS

<u>Tests</u>	<u>Date</u>	<u>Value</u>	<u>Unit</u>	<u>Normal Range</u>
free serum calcium	09/09/2007	1	mmol/L	1.15 - 1.3
serum sodium	09/09/2007	128	mmol/L	135 - 145
WBC count	09/12/2007	1	10 <sup>9</sup> /L	4.5 - 11.3
absolute neutrophil count	09/12/2007	0.02	10 <sup>9</sup> /L	1.8 - 7.00
body temp	09/12/2007	38.2	C	
free serum calcium	09/12/2007	1	mmol/L	1.15 - 1.3
neutrophil count	09/12/2007	3	%	1.8 - 7
platelet count	09/12/2007	12,000		
platelet count	09/12/2007	16	x10 <sup>9</sup> /L	140 - 150
serum sodium	09/12/2007	123	mmol/L	135 - 145
stool occult blood	09/12/2007			
Comment: positive				
WBC count	09/13/2007	1	10 <sup>9</sup> /L	4.5 - 11.3
absolute neutrophil count	09/13/2007	1	10 <sup>9</sup> /L	1.8 - 7
platelet count	09/13/2007	40	x10 <sup>9</sup> /L	140 - 150
serum phosphorus	09/13/2007	0.37	mmol/L	
blood culture	09/13/2007			
Comment: E. coli				
WBC count	09/14/2007	1	10 <sup>9</sup> /L	4.5 - 11.3
neutrophil count	09/14/2007	17	%	40 - 70
plasma HCO <sub>3</sub>	09/14/2007	16	mmol/L	12 - 31
platelet count	09/14/2007	23	10 <sup>9</sup> /L	140 - 150
serum calcium	09/14/2007	1	mmol/L	2.1 - 2.55
serum phosphorus	09/14/2007	1	mmol/L	.74 - 1.2
serum potassium	09/14/2007	3.0	mmol/L	3.5 - 5
WBC count	09/15/2007	5	10 <sup>9</sup> /L	4.5 - 11.3
neutrophil count	09/15/2007	46	%	40 - 70
plasma HCO <sub>3</sub>	09/15/2007	18	mmol/L	12 - 31
platelet count	09/15/2007	28	10 <sup>9</sup> /L	140 - 150
serum calcium	09/15/2007	1	mmol/L	2.1 - 2.55
serum phosphorus	09/15/2007	1	mmol/L	.74 - 1.2
serum potassium	09/15/2007	3	mmol/L	3.5 - 5
absolute neutrophil count	09/17/2007	4.15	10 <sup>9</sup> /L	1.8 - 7.00
platelet count	09/17/2007	123,000		
WBC count	09/18/2007	1	10 <sup>9</sup> /L	4.5 - 11.3
neutrophil count	09/18/2007	53	%	40 - 70

plasma HCO{3}	09/18/2007	22 mmol/L	12 - 31
platelet count	09/18/2007	207 $10^9/L$	140 - 150
serum calcium	09/18/2007	1 mmol/L	2.1 - 2.55
serum potassium	09/18/2007	1 mmol/L	3.5 - 5
absolute neutrophil count	10/??/2007	$2.1 \times 10^9/L$	1.96 - 7.23
Comment: cycle 2			
absolute neutrophil count	10/05/2007	$0.58 \times 10^9/L$	1.96 - 7.23
Comment: cycle 2, Day 8			
absolute neutrophil count	10/07/2007	$0.11 \times 10^9/L$	1.8 - 7
absolute neutrophil count	10/07/2007		1.8 - 7
body temp	10/07/2007	38.7 C	
hemoglobin	10/07/2007	119 g/L	135 - 175
platelet count	10/07/2007	52 $\times 10^9/L$	140 - 150
blood culture	10/07/2007		
Comment: hemoculture - negative			
absolute neutrophil count	10/08/2007		1.8 - 7
platelet count	10/08/2007	35 $\times 10^9/L$	140 - 150
absolute neutrophil count	10/10/2007	$5.08 \times 10^9/L$	1.8 - 7
absolute neutrophil count	10/10/2007		1.8 - 7
WBC count	10/25/2007		4.5 - 11.3
absolute neutrophil count	10/25/2007	$1.39 \times 10^9/L$	
absolute neutrophil count	10/25/2007		1.8 - 7
body temp	10/25/2007	39.1 C	
platelet count	10/25/2007	53 $\times 10^9/L$	140 - 150
pulse oximetry	10/25/2007	91 %	
respiratory rate measurement	10/25/2007	28 /minute	
blood culture	10/25/2007	negative	
hemoglobin	10/29/2007	86 g/L	135 - 175
absolute neutrophil count	10/31/2007	$4.56 \times 10^9/L$	
white blood cell differential	09/12/2008	negative	
neutrophil count	09/17/2008	56 %	

## 7. Other relevant history including preexisting medical conditions

Heartburn; Haemoptysis; Insomnia; Cataract

## C. Suspect medication(s)

## 1. Name (Give labeled strength &amp; mfr/labeler)

#1 CAP 0683-blinded therapy Unk  
 #1 CAP 0683-blinded therapy Unk  
 #2 infusion (form) carboplatin Unk  
 #2 infusion (form) carboplatin Unk  
 #2 infusion (form) carboplatin Unk  
 #3 infusion (form) paclitaxel 200 mg  
 #3 infusion (form) paclitaxel 150 mg  
 #3 infusion (form) paclitaxel 200 mg

## 2. Dose, frequency &amp; route used

#1 Unk/Unk/PO  
 #1 Unk/Unk/PO  
 #2 685 mg/1X/IV  
 #2 560 mg/1X/IV  
 #2 585 mg/1X/IV  
 #3 388 mg/1X/IV  
 #3 290 mg/1X/IV  
 #3 294 mg/1X/IV

## 3. Therapy dates (if unknown, give duration) from/to (or best estimate)

#1 09/28/2007 - 10/09/2007  
 #1 10/18/2007 - 10/25/2007  
 #2 09/04/2007 - 09/04/2007  
 #2 09/28/2007 - 09/28/2007  
 #2 10/18/2007 - 10/18/2007  
 #3 09/04/2007 - 09/04/2007  
 #3 09/28/2007 - 09/28/2007  
 #3 10/18/2007 - 10/18/2007

## 4. Diagnosis for use (indication)

#1 Non-small cell lung cancer  
 #1 Non-small cell lung cancer  
 #2 Non-small cell lung cancer  
 #2 Non-small cell lung cancer  
 #2 Non-small cell lung cancer  
 #3 Non-small cell lung cancer  
 #3 Non-small cell lung cancer  
 #3 Non-small cell lung cancer

## 5. Event abated after use stopped or dose reduced

	YES	NO	N/A	UNK
#1			X	
#1			X	
#2				X
#2				X
#2				X
#3			X	
#3			X	
#3			X	

## 6. Lot # (if known)

#1  
 #1  
 #2  
 #2  
 #2  
 #3  
 #3  
 #3

## 7. Exp date (if known)

#1  
 #1  
 #2  
 #2  
 #2  
 #3  
 #3  
 #3

## 8. Event reappeared after reintroduction

	YES	NO	N/A	UNK
#1			X	
#1			X	
#2				X
#2				X
#2				X
#3			X	
#3			X	
#3			X	

## C. Suspect medication(s)

10. Concomitant medical products and therapy dates (exclude treatment of event)

dexamethasone	10/17/2007 - 10/19/2007
diphenhydramine hydrochloride	09/04/2007 - 09/04/2007
diphenhydramine hydrochloride	09/28/2007 - 09/28/2007
diphenhydramine hydrochloride	10/18/2007 - 10/18/2007
dolasetron mesylate	09/04/2007 - 09/04/2007
dolasetron mesylate	09/28/2007 - 09/28/2007
dolasetron mesylate	10/18/2007 - 10/18/2007
famotidine	09/04/2007 - 09/04/2007
famotidine	09/28/2007 - 09/28/2007
famotidine	10/18/2007 - 10/18/2007
ibuprofen	01/??/2007 - 12/17/2007
indomethacin	01/??/2007 - Cont